Production of Recombinant Immunotherapeutics for Anticancer Treatment: the Role of Bioengineering

Overview

Journal Bioengineered

Date 2013 May 7

PMID 23644447

Citations 10

Authors

Maria-Cristina S Pranchevicius

Thiessa R Vieira

Affiliations

Soon will be listed here.

Abstract

Cancer is one of the most important health problems because many cases are difficult to prevent. Cancer still has unknown mechanisms of pathogenesis, and its capacity to produce temporary or permanent damage, besides death, is very high. Although many anticancer therapies are available, finding a cure for cancer continues to be a difficult task. Thus, many efforts have been made to develop more effective treatments, such as immunotherapy based on a new class of tumor-specific products that are produced using recombinant DNA technology. These recombinant products are used with the main objectives of killing the tumor and stimulating immune cells to respond to the cancer cells. The principal recombinant products in anticancer therapy are immunostimulants, vaccines, antibodies, immunotoxins and fusion proteins. This review focuses on the general aspects of these genetically engineered products, their clinical performance, current advances and future prospects for this type of anticancer therapy.

Citing Articles

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.

Sheikhlary S, Lopez D, Moghimi S, Sun B Biomolecules. 2024; 14(4).

PMID: 38672519 PMC: 11048403. DOI: 10.3390/biom14040503.

Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs.

Tombacz I, Laczko D, Shahnawaz H, Muramatsu H, Natesan A, Yadegari A Mol Ther. 2021; 29(11):3293-3304.

PMID: 34091054 PMC: 8571164. DOI: 10.1016/j.ymthe.2021.06.004.

Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review.

Anderson W, Cruz N, Lima L, Emerson G, Rodrigues E, Melo G Int J Retina Vitreous. 2021; 7(1):37.

PMID: 33962696 PMC: 8103589. DOI: 10.1186/s40942-021-00307-7.

Comparative analytical profiling of bevacizumab biosimilars marketed in India: a national control laboratory study.

Prakash A, Mishra N, Vaish U, Sharma S, Anand A, Mahajan R 3 Biotech. 2020; 10(12):516.

PMID: 33194520 PMC: 7652956. DOI: 10.1007/s13205-020-02506-9.

Antimicrobial activities and mechanism of action of Cymbopogon khasianus (Munro ex Hackel) Bor essential oil.

Singh G, Katoch M BMC Complement Med Ther. 2020; 20(1):331.

PMID: 33153473 PMC: 7643435. DOI: 10.1186/s12906-020-03112-1.

References

Oldham R, Dillman R . Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol. 2008; 26(11):1774-7. DOI: 10.1200/JCO.2007.15.7438. View

Grillo-Lopez A . Rituximab (Rituxan/MabThera): the first decade (1993-2003). Expert Rev Anticancer Ther. 2003; 3(6):767-79. DOI: 10.1586/14737140.3.6.767. View

Dillman R . Cancer immunotherapy. Cancer Biother Radiopharm. 2011; 26(1):1-64. DOI: 10.1089/cbr.2010.0902. View

Jeong K, Jang S, Velmurugan N . Recombinant antibodies: engineering and production in yeast and bacterial hosts. Biotechnol J. 2010; 6(1):16-27. DOI: 10.1002/biot.201000381. View

Choudhary S, Mathew M, Verma R . Therapeutic potential of anticancer immunotoxins. Drug Discov Today. 2011; 16(11-12):495-503. DOI: 10.1016/j.drudis.2011.04.003. View

Hornig N, Farber-Schwarz A . Production of bispecific antibodies: diabodies and tandem scFv. Methods Mol Biol. 2012; 907:713-27. DOI: 10.1007/978-1-61779-974-7_40. View

Modjtahedi H, Ali S, Essapen S . Therapeutic application of monoclonal antibodies in cancer: advances and challenges. Br Med Bull. 2012; 104:41-59. DOI: 10.1093/bmb/lds032. View

Aldrich J, Lowe D, Shearer M, Winn R, Jumper C, Kennedy R . Vaccines and immunotherapeutics for the treatment of malignant disease. Clin Dev Immunol. 2010; 2010:697158. PMC: 2948924. DOI: 10.1155/2010/697158. View

Pillay V, Gan H, Scott A . Antibodies in oncology. N Biotechnol. 2011; 28(5):518-29. DOI: 10.1016/j.nbt.2011.03.021. View

10.

Mitchell E . Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clin Colorectal Cancer. 2012; 12(2):73-85. DOI: 10.1016/j.clcc.2012.08.001. View

11.

Armstrong E . Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010; 16(3):217-30. PMC: 10437588. DOI: 10.18553/jmcp.2010.16.3.217. View

12.

Higano C, Schellhammer P, Small E, Burch P, Nemunaitis J, Yuh L . Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16):3670-9. DOI: 10.1002/cncr.24429. View

13.

Liu X, Pop L, Vitetta E . Engineering therapeutic monoclonal antibodies. Immunol Rev. 2008; 222:9-27. DOI: 10.1111/j.1600-065X.2008.00601.x. View

14.

Nemunaitis J . Multifunctional vaccines in cancer: the 'triad' approach. Expert Rev Vaccines. 2011; 10(6):713-5. DOI: 10.1586/erv.11.78. View

15.

Moschella F, Proietti E, Capone I, Belardelli F . Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann N Y Acad Sci. 2010; 1194:169-78. DOI: 10.1111/j.1749-6632.2010.05464.x. View

16.

Yusibov V, Streatfield S, Kushnir N . Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin. 2011; 7(3):313-21. DOI: 10.4161/hv.7.3.14207. View

17.

Bolhassani A, Mohit E, Rafati S . Different spectra of therapeutic vaccine development against HPV infections. Hum Vaccin. 2009; 5(10):671-89. DOI: 10.4161/hv.5.10.9370. View

18.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

19.

Giantonio B, Catalano P, Meropol N, ODwyer P, Mitchell E, Alberts S . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25(12):1539-44. DOI: 10.1200/JCO.2006.09.6305. View

20.

Holt L, Herring C, Jespers L, Woolven B, Tomlinson I . Domain antibodies: proteins for therapy. Trends Biotechnol. 2003; 21(11):484-90. DOI: 10.1016/j.tibtech.2003.08.007. View